AMPK Energy Sensing Pathway

AMP-activated protein kinase is the cellular energy sensor that activates catabolic pathways and inhibits anabolic processes when cellular energy is low. A key target for metabolic diseases, cancer, and longevity.

Overview

AMPK is a heterotrimeric kinase (α, β, γ subunits) activated by rising AMP:ATP and ADP:ATP ratios during energy stress. Upstream kinases LKB1 and CaMKKβ phosphorylate AMPKα at Thr172. Active AMPK phosphorylates >100 substrates to restore energy balance: inhibiting mTORC1 (growth), ACC (fatty acid synthesis), and HMGCR (cholesterol synthesis) while activating glucose uptake, fatty acid oxidation, and autophagy.

Key Steps

1. Cellular energy depletion raises AMP:ATP ratio
2. AMP binds AMPKγ subunit, causing conformational change protecting Thr172 phosphorylation
3. LKB1 phosphorylates AMPKα-Thr172 (constitutively active, AMPK state-dependent)
4. Active AMPK phosphorylates TSC2 and Raptor → mTORC1 inhibition → autophagy activation
5. AMPK phosphorylates ACC1/2 → fatty acid oxidation increase, lipogenesis decrease
6. AMPK promotes GLUT4 translocation → glucose uptake in muscle

Disease Relevance

• Cancer: AMPK activation opposes the Warburg effect by promoting oxidative phosphorylation. Loss of LKB1 (upstream AMPK activator) is a common tumor suppressor mutation.
• Aging: AMPK activation mimics caloric restriction effects. Metformin's longevity benefits are partly AMPK-mediated. AMPK declines with age.
• Alzheimer's: AMPK activation promotes autophagy-mediated Aβ clearance and reduces tau phosphorylation. But excessive AMPK in neurons may increase Aβ production — context matters.

Therapeutic Targets

• Metformin: Complex I inhibition raises AMP:ATP → AMPK activation
• Berberine: Similar mechanism to metformin — mitochondrial Complex I inhibition
• EGCG: Direct AMPK activation via CaMKKβ pathway
• Quercetin: AMPK activation and SIRT1 upregulation